Markets:

Overview

News

Currencies

International

Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

9.335 +0.025 (+0.27%)

Streaming Delayed Price Updated: 9:52 AM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stocks That Hit 52-Week Lows On Thursday ↗

October 05, 2023

On Thursday, 369 companies hit new 52-week lows.

Via Benzinga

Expert Ratings for Prothena Corp ↗

August 22, 2023

Via Benzinga

JMP Securities Maintains Outperform Rating for Prothena Corp: Here's What You Need To Know ↗

August 04, 2023

Via Benzinga

Earnings Scheduled For August 3, 2023 ↗

August 03, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.

Via Benzinga

Prothena Corp's Earnings Outlook ↗

August 02, 2023

Via Benzinga

Prothena to Participate in Upcoming Healthcare Conferences

August 31, 2023

From Prothena Corporation plc

Via Business Wire

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

August 03, 2023

From Prothena Corporation plc

Via Business Wire

Prothena to Report Second Quarter 2023 Financial Results on August 3

July 27, 2023

From Prothena Corporation plc

Via Business Wire

Prothena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference® 2023 (AAIC®)

July 17, 2023

From Prothena Corporation plc

Via Business Wire

Expert Ratings for Prothena Corp ↗

July 11, 2023

Via Benzinga

8 Analysts Have This to Say About Prothena Corp ↗

June 21, 2023

Via Benzinga

Prothena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)

July 11, 2023

From Prothena Corporation plc

Via Business Wire

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

July 10, 2023

From Prothena Corporation plc

Via Business Wire

Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab

June 27, 2023

From Prothena Corporation plc

Via Business Wire

Looking Into Prothena Corp's Return On Capital Employed ↗

May 16, 2023

Via Benzinga

Recap: Prothena Corp Q1 Earnings ↗

May 04, 2023

Via Benzinga

Prothena to Participate in Jefferies 2023 Healthcare Conference

June 02, 2023

From Prothena Corporation plc

Via Business Wire

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors

May 16, 2023

From Prothena Corporation plc

Via Business Wire

Prothena Reports First Quarter 2023 Financial Results and Business Highlights

May 04, 2023

From Prothena Corporation plc

Via Business Wire

Prothena Corp Earnings Preview ↗

May 03, 2023

Via Benzinga

Where Prothena Corp Stands With Analysts ↗

April 24, 2023

Via Benzinga

The Latest Analyst Ratings for Prothena Corp ↗

April 03, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

May 04, 2023

Via Benzinga

Another Sucess In Alzheimer’s Disease ↗

May 03, 2023

Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments?

Via Talk Markets

Prothena to Report First Quarter 2023 Financial Results on May 4

April 27, 2023

From Prothena Corporation plc

Via Business Wire

Prothena to Participate in 2023 Bank of America Healthcare Conference

April 24, 2023

From Prothena Corporation plc

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023 ↗

April 24, 2023

Via Benzinga

Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial

April 13, 2023

From Walgreens

Via Business Wire

Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

March 31, 2023

From Prothena Corporation plc

Via Business Wire

Prothena to Participate in Stifel 2023 Virtual CNS Days

March 21, 2023

From Prothena Corporation plc

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.